[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Korro Bio Inc (KRRO)

Korro Bio Inc (KRRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 201,778
  • Shares Outstanding, K 14,423
  • Annual Sales, $ 6,390 K
  • Annual Income, $ -117,260 K
  • EBIT $ -87 M
  • EBITDA $ -84 M
  • 60-Month Beta 3.20
  • Price/Sales 30.44
  • Price/Cash Flow N/A
  • Price/Book 2.47

Options Overview Details

View History
  • Implied Volatility 92.39% (-10.80%)
  • Historical Volatility 81.97%
  • IV Percentile 15%
  • IV Rank 8.86%
  • IV High 316.82% on 02/13/26
  • IV Low 70.56% on 12/11/25
  • Expected Move (DTE 22) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 8
  • Volume Avg (30-Day) 137
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 2,336
  • Open Int (30-Day) 6,897
  • Expected Range 13.89 to 13.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.60
  • Number of Estimates 5
  • High Estimate $-1.05
  • Low Estimate $-2.17
  • Prior Year $-2.49
  • Growth Rate Est. (year over year) +35.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.90 +39.60%
on 03/30/26
15.56 -11.15%
on 04/06/26
+2.55 (+22.63%)
since 03/23/26
3-Month
9.88 +39.88%
on 01/26/26
15.56 -11.15%
on 04/06/26
+3.09 (+28.80%)
since 01/23/26
52-Week
5.20 +165.54%
on 12/02/25
55.89 -75.27%
on 10/16/25
-4.14 (-23.05%)
since 04/23/25

Most Recent Stories

More News
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences

American Society of Gene and Cell Therapy 29 th Annual Meeting (ASGCT) TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference 3 rd International Conference on Ureagenesis Defects...

KRRO : 13.68 (-2.22%)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and...

KRRO : 13.68 (-2.22%)
Top 5 Insider Buys From Q1: Buy, Sell, or Hold in Q2?

Insiders aggressively bought these stocks, signaling confidence in their operations. The question is whether others think the same.

SSP : 4.93 (-2.18%)
SVC : 1.4750 (-3.59%)
WRB : 67.64 (+0.21%)
KRRO : 13.68 (-2.22%)
CPNG : 20.70 (+0.49%)
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for alpha-1...

KRRO : 13.68 (-2.22%)
Korro Announces Oversubscribed $85 Million Private Placement

Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA...

KRRO : 13.68 (-2.22%)
Korro to Present at the TD Cowen 46th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly...

KRRO : 13.68 (-2.22%)
Korro to Host Virtual Analyst Day on January 27, 2026

- Program to feature presentations from the company management about  KRRO-121 for the potential treatment of hyperammonemia , a leading clinical hepatologist about ammonia-driven diseases, and a caregiver...

KRRO : 13.68 (-2.22%)
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44 th Annual...

KRRO : 13.68 (-2.22%)
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- — KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients     — KRRO-110 did not reach projected...

KRRO : 13.68 (-2.22%)
Korro Bio CFO Vineet Agarwal Resigns, Interim Appointed

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Korro Bio...

KRRO : 13.68 (-2.22%)

Business Summary

Korro Bio Inc. is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. Korro Bio Inc., formerly known as Frequency Therapeutics Inc., is based in LEXINGTON, Mass.

See More

Key Turning Points

3rd Resistance Point 14.61
2nd Resistance Point 14.33
1st Resistance Point 14.16
Last Price 13.68
1st Support Level 13.71
2nd Support Level 13.43
3rd Support Level 13.26

See More

52-Week High 55.89
Fibonacci 61.8% 36.53
Fibonacci 50% 30.55
Fibonacci 38.2% 24.57
Last Price 13.68
52-Week Low 5.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.